Buy Cortifen 200.25 Injection Online

Cortifen 200.25 Injection is a veterinary injectable anti-inflammatory product associated with Agrovet Market Animal Health. Available product information identifies its formulation as phenylbutazone 200 mg/mL combined with dexamethasone 21-phosphate 0.33 mg/mL. It is described as an anti-inflammatory, antipyretic and analgesic veterinary medicine, with applications involving inflammatory and painful conditions of the locomotor system and other inflammatory processes.

For equine-focused buyers, the product is particularly relevant because published Agrovet Market information identifies horses among the intended species and describes veterinary use in locomotor-system conditions. The same sources also list cattle, sheep, goats, pigs and companion animals, although the exact authorized species and uses can depend on the product registration and jurisdiction.

Because Cortifen 200.25 combines an NSAID with a corticosteroid and is supplied as an injectable veterinary medicine, it should be treated as a professional-use product rather than an ordinary supplement. Veterinary assessment is important before use, particularly when the animal has other medical conditions or is receiving other anti-inflammatory medicines.

---

What Is Cortifen 200.25 Injection?

Cortifen 200.25 Injection is an injectable veterinary anti-inflammatory formulation containing two pharmacologically active components:

• Phenylbutazone — 200 mg/mL
• Dexamethasone 21-phosphate — 0.33 mg/mL

The product is manufactured by Agrovet Market Animal Health, according to published veterinary product information. It is also identified under the related product name Dexabutazon 200.25.

The combination brings together two different anti-inflammatory drug classes. Phenylbutazone is a non-steroidal anti-inflammatory drug (NSAID), while dexamethasone is a corticosteroid. This makes Cortifen 200.25 different from a product containing phenylbutazone alone.

Published product information describes Cortifen 200.25 as having anti-inflammatory, antipyretic and analgesic properties and associates its veterinary use with inflammatory conditions affecting the locomotor system, as well as several other inflammatory processes.

For equine professionals, understanding this formulation is especially important. The presence of both an NSAID and corticosteroid means treatment decisions should take into account the animal’s overall condition, concurrent medications, previous treatments and the reason anti-inflammatory therapy is being considered.

---

Cortifen 200.25 Injection Overview

The published Agrovet Market catalog identifies Cortifen 200.25 as an injectable solution containing phenylbutazone and dexamethasone 21-phosphate.

---

Key Features of Cortifen 200.25 Injection

Dual anti-inflammatory formulation

The defining characteristic of Cortifen 200.25 is its combination of an NSAID and a corticosteroid.

Phenylbutazone contributes NSAID activity, while dexamethasone provides corticosteroid anti-inflammatory activity. The combination therefore differs pharmacologically from single-ingredient phenylbutazone products.

Injectable veterinary formulation

Cortifen 200.25 is supplied as an injectable solution. Published product information identifies parenteral administration and reports deep intramuscular or intravenous administration in its product literature.

Because injectable medicines require appropriate handling and administration technique, they should be used by or under the direction of a qualified veterinary professional.

Equine relevance

Agrovet Market’s published material specifically includes horses among the species associated with Cortifen 200.25 and categorizes the product within equine anti-inflammatory products.

Multiple package sizes

Available product references list several presentations, including 10 mL, 20 mL, 50 mL, 100 mL, 250 mL and 500 mL. However, not every presentation is necessarily marketed or registered in every country.

Veterinary-use positioning

Cortifen 200.25 is a pharmaceutical product rather than a nutritional supplement. Its use should therefore be based on a veterinary assessment of the individual animal.

---

Product Details

Active ingredient: Phenylbutazone

Each mL contains 200 mg of phenylbutazone according to the published formulation.

Phenylbutazone belongs to the NSAID family and is widely recognized in veterinary medicine for its anti-inflammatory and analgesic properties. Its inclusion makes the product relevant to inflammatory and painful musculoskeletal conditions when a veterinarian determines that phenylbutazone is appropriate.

Active ingredient: Dexamethasone 21-phosphate

The formulation also contains 0.33 mg/mL dexamethasone 21-phosphate.

Dexamethasone is a corticosteroid with potent anti-inflammatory activity. Corticosteroids act through mechanisms different from those of NSAIDs, which is why the combination represents a distinct pharmacological approach.

Concentration

The product’s “200.25” designation corresponds closely with its two principal active components:

• Phenylbutazone: 200 mg/mL
• Dexamethasone 21-phosphate: 0.33 mg/mL

The formulation should not be confused with phenylbutazone-only injectable products that may have similar packaging or concentrations.

---

Understanding Phenylbutazone

Phenylbutazone is an NSAID used in veterinary medicine, particularly in the management of inflammatory and painful musculoskeletal conditions.

The Cortifen product insert explains that phenylbutazone’s activity involves interference with prostaglandin production, which is part of the body’s inflammatory and pain signaling processes.

In practical veterinary terms, this pharmacological activity helps explain why phenylbutazone-containing medicines may be considered in situations involving inflammation, pain and musculoskeletal dysfunction.

However, the presence of phenylbutazone does not mean that every painful condition is automatically suitable for treatment with Cortifen 200.25. The underlying diagnosis remains important.

---

Understanding Dexamethasone

Dexamethasone is a corticosteroid. Corticosteroids have potent effects on inflammatory and immune responses.

In Cortifen 200.25, dexamethasone 21-phosphate is combined with phenylbutazone. This means the medicine contains both an NSAID and a corticosteroid rather than simply increasing the amount of a single anti-inflammatory compound.

That distinction matters when reviewing a horse’s existing treatment plan.

A veterinarian should consider:

• Current anti-inflammatory medications
• Previous NSAID treatment
• Corticosteroid exposure
• Gastrointestinal history
• Kidney function
• Hydration status
• Existing disease
• Pregnancy or reproductive status where relevant
• Competition regulations
• Whether the animal is intended for food production

---

Veterinary and Equine Considerations

Cortifen 200.25 has documented relevance to veterinary management of the locomotor system. Agrovet Market information describes the product for primary locomotor-system conditions and inflammatory processes associated with osteopathies, adenopathies and neuropathies, among other contexts.

For horses, this makes the product particularly relevant to veterinary discussions involving inflammation and painful musculoskeletal conditions.

However, a product page should not be interpreted as a diagnosis. Musculoskeletal pain in horses can have many causes, including:

• Soft-tissue injury
• Joint inflammation
• Tendon or ligament problems
• Bone injury
• Hoof-related pain
• Trauma
• Infection
• Neurological conditions
• Mechanical abnormalities
• Chronic degenerative processes

The underlying cause should be evaluated before deciding which pharmaceutical approach is appropriate.

---

How Cortifen 200.25 Is Used

Published product information describes Cortifen 200.25 as being used in veterinary treatment programs involving inflammatory and painful conditions, particularly those affecting the locomotor system. It is also described in connection with certain infectious-arthritis treatment programs as a coadjuvant to antimicrobial therapy.

This wording is important: Cortifen 200.25 is not an antibiotic.

Where infection is suspected, an anti-inflammatory product cannot replace appropriate diagnosis and antimicrobial management. The underlying infection needs veterinary attention.

The product may be considered when a veterinarian determines that controlling inflammatory and painful components is appropriate as part of a broader treatment plan.

---

Benefits and Important Considerations

Anti-inflammatory activity

Both components contribute anti-inflammatory pharmacology, although they work through different mechanisms.

Analgesic relevance

The product is described by its manufacturer-related product information as analgesic as well as anti-inflammatory.

Pain relief can be an important component of veterinary management, but reducing visible pain does not necessarily resolve the underlying cause.

Antipyretic properties

Cortifen 200.25 is also categorized as antipyretic in available product descriptions.

Fever is a clinical sign rather than a diagnosis, so identifying the reason for fever remains important.

Dual-drug considerations

The most important consideration is also one of the product’s defining characteristics: it combines an NSAID and a corticosteroid.

This means it should not automatically be treated as interchangeable with a phenylbutazone-only product or a dexamethasone-only product.

---

Important Safety Information

Cortifen 200.25 should be used under veterinary direction.

The combination of phenylbutazone and dexamethasone requires particular attention to the animal’s medical history and concurrent medication.

Do not assume compatibility with other anti-inflammatory drugs

A horse may already be receiving an NSAID or corticosteroid. Adding another anti-inflammatory medicine without professional guidance can create unnecessary risk.

Veterinary review is especially important before combining Cortifen 200.25 with:

• Other NSAIDs
• Corticosteroids
• Salicylate-containing medicines
• Other drugs affecting renal function
• Medicines with gastrointestinal effects

The manufacturer-associated insert contains drug-interaction information, demonstrating that interaction considerations are relevant to this formulation.

Gastrointestinal considerations

NSAIDs can affect protective gastrointestinal mechanisms. Corticosteroids also have important systemic effects.

Therefore, a history of gastrointestinal disease should be discussed with the attending veterinarian.

Kidney and hydration considerations

Veterinary assessment should also consider hydration and renal status, particularly when NSAID therapy is contemplated.

Pregnancy and reproductive status

Pregnant animals require special veterinary consideration when pharmaceutical treatment is being evaluated. Product information available online contains reproductive-related precautions, but exact restrictions should be checked against the current label applicable to the animal’s jurisdiction.

Not a general-purpose performance product

Although Cortifen 200.25 is associated with equine veterinary care, it should not be treated as a routine performance-enhancement product.

The purpose of pharmaceutical anti-inflammatory treatment is clinical management, not simply changing how a healthy horse performs.

---

Precautions and Contraindications

The exact contraindications and precautions applicable to Cortifen 200.25 should be taken from the current product insert and local registration.

This is particularly important because the product is registered differently across markets.

Available Peruvian product information identifies a SENASA registration, while commercial and veterinary databases describe different presentations and market contexts.

Before purchasing or using the product, a buyer should verify:

• Current registration status
• Authorized species
• Authorized indications
• Required prescription status
• Current package presentation
• Contraindications
• Drug interactions
• Withdrawal requirements
• Storage instructions
• Local import requirements

---

Product Form, Strength and Presentation

Cortifen 200.25 is supplied as an injectable solution.

Available product references identify these commercial presentations:

• 10 mL
• 20 mL
• 50 mL
• 100 mL
• 250 mL
• 500 mL

The Agrovet Market catalog specifically lists these presentations.

Availability can vary by country, distributor and registration status, so the package size shown by a seller should be checked before ordering.

If a listing states Cortifen 200.25 Injection without identifying the manufacturer or formulation, buyers should confirm that it is the Agrovet Market product and that the concentration matches the expected formulation.

---

Storage and Handling

Storage requirements should be taken from the current manufacturer’s packaging and product insert supplied with the particular presentation.

For injectable medicines, responsible handling generally includes:

• Keeping the container appropriately closed
• Protecting the product from unsuitable environmental conditions
• Avoiding contamination
• Checking the expiration date before use
• Inspecting the solution and container before administration
• Following the manufacturer’s storage temperature requirements
• Keeping medicines away from unauthorized access
• Disposing of unused medicine and packaging according to applicable veterinary-pharmaceutical requirements

Do not assume that storage instructions for another phenylbutazone or dexamethasone injection apply automatically to Cortifen 200.25.

---

Administration Considerations

Published product information identifies parenteral administration and reports deep intramuscular or intravenous administration for the product.

Because Cortifen 200.25 is an injectable medicine, administration should be performed by a veterinarian or appropriately trained professional according to the applicable product label.

This page intentionally does not provide a dosing schedule. Although dosing information appears in publicly available product references, dosage depends on factors including species, age, body condition, diagnosis, concurrent treatment and jurisdiction. A veterinarian should determine the appropriate regimen using the current authorized label.

---

Performance Horses and Competition Considerations

This section is especially important for owners and professionals working with sport horses.

Cortifen 200.25 contains phenylbutazone and dexamethasone, both of which can be relevant to competition medication rules.

Competition organizations may regulate:

• Phenylbutazone
• Corticosteroids
• Detection thresholds
• Permitted therapeutic use
• Withdrawal or detection periods
• Documentation requirements

These rules are not universal.

A horse competing under one organization may be subject to rules that differ from another organization or jurisdiction. Therefore, World Equine Vet does not recommend relying on a generic internet statement about whether Cortifen 200.25 is “competition safe.”

Before treatment of a competition horse, owners and trainers should consult the applicable governing body’s current medication rules and their veterinarian.

---

Food-Producing Animals

Published product information associates Cortifen 200.25 with several livestock species, including cattle, sheep, goats and pigs.

This creates an additional regulatory consideration: withdrawal periods and food-animal restrictions must be checked against the current approved label for the specific country.

A withdrawal period from one jurisdiction should never be assumed to apply internationally.

If an animal or its products may enter the human food chain, the responsible veterinarian and local regulatory requirements should determine whether the medicine is appropriate and what withdrawal requirements apply.

---

Why Veterinary Supervision Matters

Cortifen 200.25 is not simply a product where the concentration alone determines suitability.

A veterinarian may need to assess:

1. What is causing the animal’s pain or inflammation?
2. Is an NSAID appropriate?
3. Is a corticosteroid appropriate?
4. Is the combination appropriate?
5. Is the animal receiving another NSAID?
6. Is the animal receiving a corticosteroid?
7. Is there gastrointestinal or renal risk?
8. Is the animal dehydrated?
9. Is the animal intended for competition?
10. Is the animal intended for food production?
11. What product registration applies locally?

This approach helps prevent inappropriate use of a pharmaceutical product simply because it is marketed for a particular species.

---

Purchasing Considerations

When purchasing Cortifen 200.25 Injection, buyers should pay attention to more than price.

Confirm the formulation

The published formulation is:

Phenylbutazone 200 mg/mL + dexamethasone 21-phosphate 0.33 mg/mL.

Confirm the manufacturer

The product is associated with Agrovet Market Animal Health.

Confirm package size

Available references list multiple package sizes, but local availability can differ.

Check labeling

The container should clearly identify the product, concentration, manufacturer information, lot/batch details and expiry information as applicable.

Consider jurisdiction

A product marketed in Peru or another Latin American market may not have the same authorization status in the United States, Canada, Australia, the United Kingdom or the European Union.

International buyers should therefore verify import and veterinary-medicine requirements before placing an order.

---

Where To Buy Cortifen 200.25 Injection Online

If you are researching where to buy Cortifen 200.25 Injection online, World Equine Vet can provide a convenient starting point for reviewing product information and purchasing considerations.

The most important point is to make sure the product being offered is the correct Cortifen 200.25 formulation rather than a similarly named phenylbutazone product or another dexamethasone combination.

A responsible purchasing process should include checking:

• Exact product name
• Manufacturer
• Active ingredients
• Concentration
• Package size
• Expiration information
• Product labeling
• Country of origin
• Applicable veterinary requirements
• Shipping restrictions
• Import requirements where relevant

Because this is a veterinary pharmaceutical injection, availability and legal sale can differ significantly between countries. World Equine Vet should therefore be viewed as a source for product purchasing information rather than a substitute for the requirements imposed by local veterinary authorities.

For international customers, including buyers researching veterinary medicines in North America, Europe, Australia and other markets, it is particularly important to verify whether the product can legally be supplied and used in the destination country.

---

Frequently Asked Questions

What is Cortifen 200.25 Injection?

Cortifen 200.25 is an injectable veterinary anti-inflammatory formulation containing phenylbutazone 200 mg/mL and dexamethasone 21-phosphate 0.33 mg/mL. It is associated with Agrovet Market Animal Health.

Is Cortifen 200.25 used in horses?

Yes. Published Agrovet Market information identifies horses among the species associated with the product and describes veterinary applications involving locomotor-system conditions.

What are the active ingredients in Cortifen 200.25?

Each mL contains 200 mg phenylbutazone and 0.33 mg dexamethasone 21-phosphate according to the manufacturer’s published formulation.

Is Cortifen 200.25 an antibiotic?

No. It is an anti-inflammatory combination. Published product information describes it as an anti-inflammatory, antipyretic and analgesic medicine. It may be described as a coadjuvant in certain infectious-arthritis treatment contexts, but it is not itself an antimicrobial.

What is phenylbutazone?

Phenylbutazone is an NSAID used in veterinary medicine for its anti-inflammatory and analgesic properties. It is one of the two active components in Cortifen 200.25.

What is dexamethasone?

Dexamethasone is a corticosteroid with potent anti-inflammatory activity. Cortifen 200.25 contains dexamethasone 21-phosphate in combination with phenylbutazone.

Can Cortifen 200.25 be combined with another NSAID?

This should not be assumed to be safe. Because Cortifen 200.25 already contains phenylbutazone, concurrent NSAID therapy requires veterinary evaluation. The manufacturer’s product information includes drug-interaction considerations.

Is Cortifen 200.25 suitable for competition horses?

Competition suitability cannot be assumed. Phenylbutazone and dexamethasone may be regulated under competition medication rules. Owners should consult the relevant competition authority and veterinarian before treating a competition horse.

What package sizes are available?

Published product references list 10, 20, 50, 100, 250 and 500 mL presentations. Actual availability may vary by market.

Is Cortifen 200.25 available internationally?

The product has been documented in Latin American veterinary product information, including a Peruvian SENASA registration. International availability and legal importation depend on the destination country’s regulations.

Can I use the dosage found online?

A dosage schedule found online should not automatically be applied to an animal. Veterinary medicines must be selected and dosed according to the current label, species, clinical condition and applicable jurisdiction. This is particularly important with a combination containing an NSAID and corticosteroid.

Is Cortifen 200.25 a supplement?

No. It is an injectable veterinary pharmaceutical product.

What should I check before buying Cortifen 200.25?

Check the manufacturer, concentration, active ingredients, package size, labeling, expiry information, local regulatory status and whether the product is legally available for the intended species and destination.

---

Final Summary

Cortifen 200.25 Injection is an injectable veterinary pharmaceutical associated with Agrovet Market Animal Health. Its published formulation contains phenylbutazone 200 mg/mL and dexamethasone 21-phosphate 0.33 mg/mL, combining an NSAID with a corticosteroid.

The product is described for inflammatory, painful and febrile veterinary conditions, with particular relevance to the locomotor system. Published Agrovet Market information identifies horses as one of the species for which the product is marketed.

Its dual-drug formulation is an important characteristic but also means that professional assessment is particularly valuable. Cortifen 200.25 should not automatically be combined with other NSAIDs or corticosteroids, and competition-horse owners need to consider current medication-control rules.

The product is reported in multiple commercial presentations, although package availability and regulatory authorization vary by market.

For customers researching Cortifen 200.25 Injection online, the key purchasing priorities are accurate formulation, legitimate labeling, appropriate package size, reliable product information and compliance with the veterinary-medicine requirements applicable to the destination country.

World Equine Vet can help customers research the product and its characteristics, while veterinary professionals remain the appropriate source for diagnosis, treatment selection and patient-specific administration decisions.

Cortifen 200.25 For the treatment of primary type affections of the locomotive system and coadjuvant to antibiotherapy treatment of infectious arthritis

For the treatment of primary type affections of the locomotive system and coadjuvant to antibiotherapy treatment of infectious arthritis. It is also indicated in inflammatory processes that are common to osteopathies, adenopathies, neuropathies and mastitis, in all which cases it combats the congestive process and painful symptoms that come along.
Dosage y administration for Cortifen 200.25:
Cattle and horses: 30 mL the first day, 20 mL the second day and then 10 mL per day during 4 – 6 days (half the dose in young animals). Sheep and goats: 5 mL/animal/day during 2 days. Pigs of 20 – 50 kg of b.w.: 5 mL/animal/day during 5 days; of 50 – 100 kg of b.w.: 10 mL/animal/day during 2 days; of more than 100 kg of b.w.: 15 mL the first day and then 10 mL per day during 4 – 6 days. Minor animals: 1 mL/15 kg of b.w. per day during 5 days. Apply through deep intramuscular or intravenous route.

CORTIFEN 200.25
Injectable Solution
Anti inflammatory, antipyretic and analgesic
Camels Canines Goats Horses Felines Sheep Swine Cattle
Formulation
Phenylbutazone 200.00mg; dexamethasone sodium phosphate 0.33 mg; exipients q.s. ad 1mL.

Indications for Cortifen 200.25
For the treatment of primary type affections of the locomotive system and coadjuvant to antibiotherapy treatment of infectious arthritis. It is also indicated in inflammatory processes that are common to osteopathies, adenopathies, neuropathies and mastitis, in all which cases it combats the congestive process and painful symptoms that come along.

Dosage and Administration for Cortifen 200.25
Cattle and horses: 30 mL the first day, 20 mL the second day and then 10 mL per day during 4 – 6 days (half the dose in young animals). Sheep and goats: 5 mL/animal/day during 2 days. Pigs of 20 – 50 kg of b.w.: 5 mL/animal/day during 5 days; of 50 – 100 kg of b.w.: 10 mL/animal/day during 2 days; of more than 100 kg of b.w.: 15 mL the first day and then 10 mL per day during 4 – 6 days. Minor animals: 1 mL/15 kg of b.w. per day during 5 days. Apply through deep intramuscular or intravenous route.

Commercial Presentation for Cortifen 200.25
Bottle x 10 mL , Bottle x 20 mL , Bottle x 50 mL , Bottle x 100 mL , Bottle x 250 mL , Bottle x 500 mL ,

SENASA Registry of Cortifen 200.25
SENASA Perú: F.85.01.N.0024

Cortifen 200.25
Print
Insert
Disclaimer
Buy now
MORE VISITED PRODUCTS for Cortifen 200.25
hematofos-b12.jpg
Hematofos B12
Injectable Solution
Multi-tonic complemented with phosphorous